Marios Mejdani,Kiandokht Haddadi,Chester Pham et al.
Marios Mejdani et al.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations can impact infectivity, viral load, and overall morbidity/mortality during infection. In this analysis, we look at the mutational landscape of the SARS-CoV-2 receptor-bi...
Using mixed-effects modeling to estimate decay kinetics of response to SARS-CoV-2 infection [0.03%]
利用混合效应模型估计SARS-CoV-2感染反应的衰减速率
Dean Bottino,Greg Hather,L Yuan et al.
Dean Bottino et al.
The duration of natural immunity in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of some debate in the literature at present. For example, in a recent publication characterizing SARS-CoV-2 immunity ov...
Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt [0.03%]
埃及新兴疫苗开发用灭活全病毒SARS-COV-2的安全性和免疫原性评估
Amani A Saleh,Mohamed A Saad,Islam Ryan et al.
Amani A Saleh et al.
Background: Current worldwide pandemic coronavirus disease 2019 (COVID-19) with high numbers of mortality rates and huge economic problems require an urgent demand for safe and effective vaccine development. Inactivated S...
Diyuan Xue,Eric Hsu,Yang-Xin Fu et al.
Diyuan Xue et al.
Most studies focus on the first and second signals of T cell activation. However, the roles of cytokines in immunotherapy are not fully understood, and cytokines have not been widely used in patient care. Clinical application of cytokines i...
Antibody heavy chain CDR3 length-dependent usage of human IGHJ4 and IGHJ6 germline genes [0.03%]
抗体重链CDR3长度依赖型使用人类IGHJ4和IGHJ6基因元基因
Huimin Wang,Kai Yan,Ruixue Wang et al.
Huimin Wang et al.
Therapeutic antibody discovery using synthetic diversity has been proved productive, especially for target proteins not suitable for traditional animal immunization-based antibody discovery approaches. Recently, many lines of evidences sugg...
An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers [0.03%]
一种新型CEA/CD3双特异性抗体对结直肠癌的抗肿瘤作用响应研究
Ninghai Wang,Harshal Patel,Irene C Schneider et al.
Ninghai Wang et al.
Background: CD3-based bispecific T cell engagers (bsTCEs) are one of the most promising bispecific antibodies for effective cancer treatments. To elicit target-specific T cell-mediated cytotoxicity, these bsTCEs contain a...
Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy [0.03%]
强力的胚系样单克隆抗体：基于抗体的抗病毒治疗的候选药物快速识别方法
Xiaoyi Zhu,Fei Yu,Yanling Wu et al.
Xiaoyi Zhu et al.
In recent years, fully human monoclonal antibodies (mAbs) are making up an increasing share of the pharmaceutical market. However, to improve affinity and efficacy of antibodies, many somatic hypermutations could be introduced during affini...
Current trends and challenges in the downstream purification of bispecific antibodies [0.03%]
双特异性抗体下游纯化的最新趋势和挑战
Serene W Chen,Wei Zhang
Serene W Chen
Bispecific antibodies (bsAbs) represent a highly promising class of biotherapeutic modality. The downstream processing of this class of antibodies is therefore of crucial importance in ensuring that these products can be obtained with high ...
Insights into CD47/SIRPα axis-targeting tumor immunotherapy [0.03%]
靶向肿瘤免疫治疗中CD47/SIRPα轴的作用机制及应对策略新进展
Xuyao Zhang,Jiajun Fan,Dianwen Ju
Xuyao Zhang
During the last decade, inhibitors targeting immune checkpoint programmed death ligand 1/PD-1 and cytotoxic T-lymphocyte-associated protein 4 have been one of the most significant advances for cancer therapy in clinic. However, most of thes...
Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities [0.03%]
Ado-曲妥珠单抗_emtansine引起的毒性的机制：对ADC相关毒性更好理解的途径
Yukinori Endo,Nishant Mohan,Milos Dokmanovic et al.
Yukinori Endo et al.
In order to improve the safety of novel therapeutic drugs, better understanding of the mechanisms of action is important. Ado-trastuzumab emtansine (also known as T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2...